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Experimental vitamin B12 deficiency in a 
human subject: a longitudinal investigation 




Based on Victor Herbert’s model for sequential stages in the development of vitamin B12 deficiency, the holotransco-
balamin (HoloTC) immunoassay has controversially been promoted as a more specific and sensitive replacement for 
the total vitamin B12 test, for the diagnosis of deficiency. There have been no longitudinal studies, by means of experi-
mental cobalamin deficiency, because ethical considerations prevent such risky studies on patients or healthy human 
volunteers. The objective was to provide a detailed record of the response of HoloTC, compared to total vitamin B12 
and metabolites, to the development of experimental vitamin B12 deficiency in an initially replete human subject. This 
54 year old male, with a vitamin B12 deficiency possibly caused by a defect in the intracellular cobalamin metabolism, 
ensured an initially replete condition by means of oral doses of cyanocobalamin supplements at 1000 μg/day for 
12 weeks. The subject then depleted himself of vitamin B12, by withholding treatment and using a low-cobalamin 
diet, until significant metabolic disturbances were observed. The responses of serum total vitamin B12 and HoloTC and 
the two metabolites, plasma methylmalonic acid and homocysteine, were monitored by weekly blood tests. HoloTC 
was not significantly more sensitive than either total serum vitamin B12 or total homocysteine, and was much less 
sensitive than methylmalonic acid. HoloTC decreased from an initial concentration of >128 pmol/L to a minimum of 
33 pmol/L on day 742, the only day on which it fell below the lower limit of the reference interval. Total vitamin B12 
decreased from an initial concentration of 606 pmol/L to a minimum of 171 pmol/L on day 728. Total homocysteine 
increased from an initial concentration of 8.4 μmol/L to a maximum of 14.2 μmol/L on day 609. Methylmalonic acid 
unexpectedly contained four distinct peaks; initially at 0.17 μmol/L, it first exceeded the upper limit of the reference 
interval on day 386, finally reaching a maximum peak of 0.90 μmol/L on day 658. The results of this experiment are 
inconsistent with Herbert’s hypothesis that HoloTC is the earliest marker of vitamin B12 deficiency, and therefore do 
not support his model for the staged development of vitamin B12 deficiency.
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Background
Based on Victor Herbert’s model for sequential stages in 
the development of vitamin B12 deficiency (Herbert 1987a, 
1994), the holotranscobalamin (HoloTC) immunoassay 
has controversially been promoted as a more specific and 
sensitive replacement for the total vitamin B12 test, for the 
diagnosis of deficiency (Axis-Shield and Abbott Laborato-
ries 2006a, b, 2007a, b; Axis-Shield 2007a, b, 2012, 2014a, b).
Other researchers have reviewed the HoloTC immu-
noassay (Morkbak et  al. 2005; Aparicio-Ugarriza 
et al. 2014). This author’s detailed review of Herbert’s 
model and the HoloTC immunoassay, and suggested 
alternative hypothesis for the development of vita-
min B12 deficiency, has been submitted to this journal 
as a separate article. Although there have been many 
published reports supporting the use of the HoloTC 
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immunoassay, several experimenters reported results 
that do not support the claim that HoloTC is the ear-
liest and most sensitive indicator of vitamin B12 defi-
ciency (Miller et al. 2005; Clarke et al. 2007; Schrempf 
et al. 2011; Palacios et al. 2013; Remacha et al. 2014).
There have been no longitudinal studies, by means 
of experimental cobalamin deficiency, because ethical 
considerations prevent such risky studies on patients or 
healthy human volunteers.
Commencing in March 2007, this author used himself 
as the subject of an experiment to investigate the sensi-
tivity of total vitamin B12, HoloTC and the two metabo-
lites, methylmalonic acid (MMA) and total homocysteine 
(tHcy), to the onset of vitamin B12 deficiency.
Objective
The objective of this study was to investigate the per-
formance of the HoloTC (Active-B12) immunoassay 
during the development of experimental vitamin B12 defi-




As a member of Committee on Publication Eth-
ics (COPE), this journal requires that experiments on 
human subjects adhere to the ethical standards of the 
Declaration of Helsinki. In particular, there must be 
informed consent of subjects, and the experiment must 
be approved and overseen by a research ethics committee 
or institutional review board. Because this author did not 
obtain informed consent, and the study did not receive 
ethics committee approval, it is necessary for the author 
to explain the reasons why publication of this report is 
ethical.
Firstly, the author was both the experimenter and the 
single subject, so the requirement for informed consent 
does not apply. There was no institutional involvement, 
so there was no possibility of coercion. The subject was 
assessed by a psychiatrist, a Fellow of the Royal Austral-
ian and New Zealand College of Psychiatrists, before the 
experiment commenced, and found to be competent to 
evaluate the risks and benefits, and to accept full respon-
sibility for the conduct of the experiment.
Secondly, the Declaration of Helsinki is silent on self-
experimentation, because it is concerned with the con-
duct of research on patients or healthy volunteers by 
others. The requirement for ethics committee approval 
therefore does not apply where the single subject is 
also the sole experimenter. Also, because there was no 
institution involved in the study, with the experiment 
conducted by an independent researcher, no ethics com-
mittee existed.
Thirdly, the experiment was not performed recklessly 
or carelessly; the subject’s condition was monitored 
weekly by a general practitioner and the psychiatrist; nei-
ther had any conflict of interests. Being qualified medi-
cal practitioners receiving all weekly pathology reports, 
both doctors were able to continually assess the condi-
tion of the subject. The subject instigated, designed and 
performed the experiment, and the doctors’ only role was 
monitoring for safety.
Lastly, the motivation for performing the experiment 
was ethical, and involved no conflict of interests. The 
author wanted to investigate the performance of the new 
HoloTC (Active B12) immunoassay, for the diagnosis 
of vitamin B12 deficiency, because he was aware of the 
potential consequences of misdiagnosis. The author was 
motivated only by the desire to gain and share knowledge, 
to advance medical science, for the benefit of patients.
Experiment design
A human subject, initially replete in vitamin B12, con-
sumed a low-cobalamin diet and gradually ceased taking 
vitamin B12 supplements to deplete the body of vitamin 
B12, culminating in significant metabolic disturbances. 
The responses of serum total vitamin B12 and HoloTC 
and the two metabolites, plasma MMA and tHcy, were 
monitored by routine blood tests. All tests were per-
formed by pathology laboratories accredited by the 
Australian National Association of Testing Authorities 
(NATA). The experiment commenced on day 0 (5 March 
2007) and ended on day 854 (6 July 2009).
The subject
The subject was this author, a 54  year old male non-
drinker and non-smoker; he had for many years con-
sumed a lacto-vegetarian diet. The subject was diagnosed 
with vitamin B12 deficiency in October 2005, based on 
low serum vitamin B12 concentration, chronic symptoms 
of abnormal sensations in the extremities and results 
of a neurological examination. Because of his history 
of vitamin B12 deficiency, possibly caused by a defect 
in the intracellular cobalamin metabolism, the subject 
had been taking 1000  μg oral cyanocobalamin daily for 
12 weeks immediately prior to this study. Previous test-
ing showed normal results for serum vitamin B12 and the 
two metabolites, homocysteine and MMA, at this level of 
supplementation.
The low‑vitamin B12 diet
The low-vitamin B12 diet was the subject’s usual vegetar-
ian diet. The only source of vitamin B12 in the diet was 
the estimated 1.8 μg/day contained in the 300 ml of milk 
added to his breakfast cereal (Food Standards Australia 
and New Zealand 2013). Although this dietary intake 
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would be adequate to maintain the vitamin B12 store in 
a healthy individual (Herbert 1987b), extensive previous 
testing in his self-experiment of 2005 showed that this 
subject would become depleted without supplements. In 
that unpublished experiment, the subject’s serum total 
vitamin B12 concentration decreased, and his MMA and 
tHcy concentrations increased, after ceasing oral cyano-
cobalamin treatment.
Nutritional precautions
Because the subject maintained his normal vegetarian 
diet, no special nutritional precautions were required. 
There were no confounding effects of deficiency of folate 
or other vitamins, minerals or protein. Previous testing 
showed normal electrolytes, liver function and red-cell 
haematology.
Changes in vitamin B12 supplementation
At day 0 the subject had been consuming 1000  μg 
oral cyanocobalamin daily for 12 weeks. On day 7, the 
supplementation was reduced in steps to reach 10  μg 
on day 112 (Fig.  1a). The dose was then increased to 
100 μg for 4 weeks, to test for the effect on the vitamin 
B12 and metabolite assays, then reduced in steps to 
reach 0 μg on day 371. The dose was then increased to 
100 μg for 10 weeks, to test for the effect on the vita-
min B12, HoloTC and metabolite assays, then reduced 
in a single step to 0 μg on day 497. The dose remained 
at 0  μg until the end of the vitamin B12 depletion 
period on day 751.
Blood sampling
Timing of vitamin B12 supplementation and blood sampling
Blood samples were collected 24 h after the last oral vita-
min B12 supplement was taken by the subject.
Blood sample collection, handling and transport
Precautions were taken to ensure that consistent and 
valid blood samples were received by the laboratories. 
The commercial clinical laboratory that performed the 
serum vitamin B12, HoloTC and haematology tests col-
lected their own samples, using professional phleboto-
mists at a government-approved collection centre. The 
same collection centre also collected and froze plasm 
samples for assay of the metabolites, homocysteine and 
MMA, by the NSW Biochemical Genetics Service; a spe-
cialised laboratory. The subject always fasted overnight, 
and was well hydrated, ensuring maximum possible con-
sistency between samples. The phlebotomy technique 
was chosen to provide the highest quality samples; tour-
niquet application was carefully controlled, and discard 
tubes were used where required. Samples were promptly 
transported from the collection centre to the commercial 
clinical laboratory, cooled on ice, to avoid deterioration. 
The frozen plasma samples for metabolite assays were 
transported, packed in dry ice, by specialised courier.
Blood sampling frequency
Blood samples for the vitamin B12 and HoloTC were col-
lected weekly. The frequency of blood sampling for the 
metabolites was adapted according to the rate of change 
of the MMA and homocysteine responses. Blood samples 
were initially collected four-weekly; this was increased 
to fortnightly and then weekly as the rate of change 
increased.
Vitamin B12 immunoassays
Serum total vitamin B12 immunoassay
Vitamin B12 was assayed weekly by the commercial clini-
cal pathology laboratory, using the Siemens Advia Cen-
taur immunoassay system with the ADVIA Centaur and 
ACS:180 Vitamin B12 Assay reagent kit (Siemens Health-
care Diagnostics 2007). The laboratory reference interval 
was given as 162–811  pmol/L and the quoted precision 
was 10 %.
Serum holotranscobalamin (HoloTC) immunoassay
HoloTC was assayed weekly by the commercial clinical 
pathology laboratory, using the Abbott AxSYM immu-
noassay analyser with the Axis-Shield AxSYM Active-
B12 reagent kit (Axis-Shield and Abbott Laboratories 
2007a). The laboratory reference interval was given as 
>35  pmol/L, with a maximum reportable concentration 
of 128 pmol/L; the quoted precision was 7 %.
Vitamin B12 metabolite assays
Plasma methylmalonic acid (MMA)
Plasma MMA was assayed at intervals from four-weekly 
to weekly, by the NSW Biochemical Genetics Ser-
vice, using tandem mass spectrometry. The measure-
ment uncertainty was 12  % and reference interval was 
0.06–0.34 μmol/L.
Plasma total homocysteine (tHcy)
Plasma tHcy was assayed at intervals from four-weekly 
to weekly, by the NSW Biochemical Genetics Ser-
vice, using tandem mass spectrometry. The measure-
ment uncertainty was 9  % and reference interval was 
4.8–13.7 μmol/L.
Haematology
Cell counts were performed by the commercial clinical 
pathology laboratory using the Sysmex XE-2100 Auto-
mated Haematology System.
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Results
Data availability
The data sets supporting all results are included in a 
Microsoft Excel spreadsheet file, Additional file 1: Table 
S1, containing charts and tables. High-resolution images 
for Figs. 1, 2, 3, 4, 5, 6 and 7 are included in a PDF file, 
Additional file 2: Figure S1, and a Microsoft PowerPoint 
file, Additional file 3: Figure S2.
Variation over time: vitamin B12 immunoassays
Serum total vitamin B12 immunoassay
The serum total vitamin B12 concentration (Fig. 1a) was 
initially 606  pmol/L, well above the lower limit of the 
laboratory reference interval of 162  pmol/L, the Bates 
and Lewis (2012) minimum of 132  pmol/L and the Oh 
and Brown (2003) minimum of 295  pmol/L, indicat-
















































a Total vitamin B12 and HoloTC vs time
B12 Dose (µg/day) Reference A B12 Low Reference B B12 Low Lab B12 RI Low
Total B12 Lab HoloTC RI Low HoloTC
























b Total vitamin B12 vs HoloTC
Total B12 vs HoloTC Lab B12 RI Low Reference A B12 Low Reference B B12 Low Lab HoloTC RI Low
Fig. 1 Serum total vitamin B12 and HoloTC. a Serum total vitamin B12 and HoloTC versus time. b Serum total vitamin B12 versus HoloTC. Reference 
A B12 low = low limit for serum vitamin B12 concentration defined by Oh and Brown (2003). Reference B B12 low = low limit for serum vitamin B12 
concentration defined by Bates and Lewis (2012). Lab B12 RI low = lower limit of serum vitamin B12 concentration reference interval defined by the 
testing laboratory. Lab HoloTC RI low = lower limit of serum holotranscobalamin concentration reference interval defined by the testing laboratory
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The concentration then fell as the oral cyanocobalamin 
supplement dose was reduced from 1000  μg/day, and 
rose again during the two short periods when the sup-
plementation was increased to 100  μg/day. On day 728, 
231 days after the supplementation was finally reduced to 
0  μg/day, the total serum vitamin B12 concentration fell 
to a minimum of 171 pmol/L; this was slightly above the 
lower limit of the laboratory reference interval, and sig-
nificantly above the Bates and Lewis minimum, but sig-
nificantly below the Oh and Brown minimum.
Serum holotranscobalamin (HoloTC) immunoassay
Results for HoloTC (Figs.  1a, 2a, 3a) were not available 
until day 196 because of unexpected delays in the initial 
setting up for this test. The HoloTC concentration on 
day 196 was reported as >128  pmol/L, above the maxi-
mum assay limit, indicating that the subject was replete 
in serum vitamin B12. The concentration fell as the oral 
cyanocobalamin supplement level was reduced, then var-
ied within a range of 60–91 pmol/L after the oral cyano-


















































a MMA and HoloTC vs time
B12 Dose (µg/day) Lab MMA RI  High MMA Lab HoloTC RI  Low HoloTC























b MMA vs HoloTC  
MMA vs HoloTC Lab MMA RI High Lab HoloTC RI Low
Fig. 2 MMA and HoloTC. a MMA and HoloTC versus time. b MMA versus HoloTC. Lab MMA RI high = upper limit of plasma methylmalonic acid 
concentration reference interval defined by the testing laboratory. Lab HoloTC RI low = lower limit of serum holotranscobalamin concentration 
reference interval defined by the testing laboratory
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concentration then fell to a first minimum, of 48 pmol/L 
on day 420, after the after the oral cyanocobalamin sup-
plement dose was reduced to 0 μg/day. The concentration 
then rose to a peak, of 118 pmol/L on day 463, after the 
oral cyanocobalamin supplement dose was increased to 
100 μg/day. The concentration then inexplicably rose, to 
a peak of 107 pmol/L on day 511, 14 days after the cyano-
cobalamin supplement dose was finally reduced to 0 μg/
day. There were other unexplained variations in HoloTC 
concentration, over a range of 41–80  pmol/L, before 
it fell to a minimum of 33  pmol/L on day 742; this was 
the only time that the concentration fell below the lower 
limit of the laboratory reference interval of 35 pmol/L.
Variation over time: vitamin B12 metabolite assays
Plasma methylmalonic acid (MMA)
Plasma MMA concentration (Figs.  2a, 4a) was not 
tested until day 112 because previous self-experimen-
tation had shown that increases above baseline would 
not occur until after serum vitamin B12 fell below about 
300  pmol/L. The MMA concentration was initially 

















































a tHcy and HoloTC vs time
B12 Dose (µg/day) Lab tHcy RI High tHcy Lab HoloTC RI Low HoloTC




















b tHcy vs HoloTC
tHcy vs HoloTC Lab tHcy RI High Lab HoloTC RI Low
Fig. 3 tHcy and HoloTC. a tHcy and HoloTC versus time. b tHcy versus HoloTC. Lab tHcy RI high = upper limit of plasma total homocysteine 
concentration reference interval defined by the testing laboratory. Lab HoloTC RI low = lower limit of serum holotranscobalamin concentration 
reference interval defined by the testing laboratory
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the laboratory reference interval of 0.34  μmol/L. The 
MMA concentration then increased, even during the 
first of the two short periods when the supplementation 
was increased to 100  μg/day, and continued to increase 
as the cyanocobalamin dose was decreased to 10 μg/day. 
The MMA concentration briefly and inexplicably fell to 
0.20 μmol/L, on day 343, after reaching an initial peak of 
0.32 μmol/L on day 330. The MMA concentration rose to 
a peak of 0.62 μmol/L on day 428, well above the upper 
limit of the laboratory reference interval, 58  days after 
the cyanocobalamin dose was initially decreased to 0 μg/
day. The MMA concentration then fell to 0.20  μmol/L 
on day 483, during the second of the two short periods 
when the supplementation was increased to 100 μg/day. 
After the cyanocobalamin dose was finally decreased 
to 0  μg/day, the MMA concentration reached another 
peak, of 0.70 μmol/L on day 483, then inexplicably fell to 
0.42 μmol/L on day 609 before reaching a maximum peak 
of 0.90 μmol/L on day 658. The MMA concentration then 


















































a Total vitamin B12 and MMA vs time
B12 Dose (µg/day) Lab B12 RI Low Reference A B12 Low Reference B B12 Low
Total B12 Lab MMA RI High MMA
























b Total vitamin B12 vs MMA
Total B12 vs MMA Lab B12 RI Low Reference A B12 Low Reference B B12 Low Lab MMA RI High
Fig. 4 Serum total vitamin B12 and MMA. a Serum total vitamin B12 and MMA versus time. b Serum total vitamin B12 versus MMA. Reference A 
B12 Low = low limit for serum vitamin B12 concentration defined by Oh and Brown (2003). Reference B B12 Low = low limit for serum vitamin B12 
concentration defined by Bates and Lewis (2012). Lab B12 RI low = lower limit of serum vitamin B12 concentration reference interval defined by the 
testing laboratory. Lab MMA RI high = upper limit of plasma methylmalonic acid concentration reference interval defined by the testing laboratory
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increasing to remain within a range of 0.34–0.45 μmol/L, 
until the cyanocobalamin dose was increased to 1000 μg/
day, then it finally fell to 0.12 μmol/L.
Plasma total homocysteine (tHcy)
As for the MMA, plasma tHcy concentration (Fig.  3a) 
was also not tested until day 112 because previous 
self-experimentation had shown that increases above 
baseline would not occur until after serum vitamin 
B12 fell below about 300  pmol/L. The tHcy concentra-
tion was initially 8.4  μmol/L, on day 112, well below 
the upper limit of the laboratory reference interval of 
13.7  μmol/L. The tHcy concentration slowly increased, 


































a HoloTC as % total B12 vs time































b HoloHc vs time
B12 Dose (µg/day) HoloHC
Fig. 5 HoloTC and Holohaptocorrin. In a, for each pair of concurrent measurements, HoloTC as % of total serum vitamin B12 = 100 × (HoloTC 
concentration/total vitamin B12 concentration). In b, for each pair of concurrent measurements, holohaptocorrin (HoloHC) = total vitamin B12 
concentration − holotranscobalamin (HoloTC) concentration
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the supplementation was increased to 100  μg/day. The 
tHcy concentration reached a maximum of 14.2 μmol/L, 
on day 609, 112 days after the cyanocobalamin dose was 
finally decreased to 0  μg/day. The tHcy concentration 
then inexplicably gradually fell, reaching 11.4  μmol/L 
before the cyanocobalamin dose was increased to 
1000 μg/day, then finally fell to 8.5 μmol/L.
Variation over time: derived data
Holotranscobalamin (HoloTC) as percentage of total serum 
vitamin B12
The HoloTC concentration, calculated as a percentage of 
the total serum vitamin B12 concentration (Fig. 5a), was 
initially 27.6 %, on day 196. The percentage HoloTC var-
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a Cumulative % change vs time



























b Concentration as % cut-off vs time
B12 Dose (µg/day) Total B12 HoloTC MMA tHcy
Fig. 6 Cumulative change and cut-off values. In a, for each measurement for each analyte, cumulative change (%) = 100 × [(initial value − current 
value)/initial value]. In b, for each measurement for each analyte, % cut-off value = 100 × (measured value/laboratory cut-off limit value)
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vitamin B12 depletion stage. During this time there were 
several distinct peaks and troughs, but these were not 
all clearly related to any change in the cyanocobalamin 
dose. One peak, of 37.6  % on day 434, occurred 6  days 
after commencement of the second of the two short peri-
ods when the supplementation was increased to 100 μg/
day, and one trough, of 21.1 % occurred 7 days after the 
end of that period. Another inexplicable peak, of 35.1 %, 
occurred after the cyanocobalamin dose was finally 
decreased to 0 μg/day. The percentage HoloTC reached a 
maximum of 44.9 % on day 777, 26 days after the cyano-
cobalamin dose was increased to 1000 μg/day.
Holohaptocorrin (HoloHC)
The HoloHC concentration, calculated by subtract-
ing the HoloTC concentration from the total vitamin 
B12 (Fig.  5b), was initially 336  pmol/L, on day 196. The 
HoloHC concentration fell to 139  pmol/L on day 428, 
before the second of the two short periods when the 




















































a Haemoglobin and red-cell count vs time













































b Haematocrit and mean cell volume vs time
B12 Dose (µg/day) Hct RI Low Haematocrit MCV RI High Mean-cell volume
Fig. 7 Haematology. In a, Hgb low = low limit for haemoglobin concentration defined by Bates and Lewis (2012); RCC low = low limit for red-cell 
count defined by Bates and Lewis (2012). In b, Hct low = low limit for haematocrit defined by Bates and Lewis (2012); MCV high = upper limit for 
mean cell volume defined by Bates and Lewis (2012)
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peak of 279 pmol/L on day 469 during that period, then 
fell to 151 pmol/L on day 518 after the cyanocobalamin 
dose was finally decreased to 0 μg/day. There were then 
two inexplicable peaks, the second reaching 256 pmol/L 
on day 694, while the cyanocobalamin dose remained at 
0  μg/day. The HoloHC concentration increased rapidly, 
from 142 to 253 pmol/L, after the cyanocobalamin dose 
was increased to 1000  μg/day, then fell inexplicably to 
150 pmol/L before rapidly rising again.
Comparisons of analyte concentration variation over time: 
vitamin B12 and metabolite assays
Cumulative change in analyte concentration as percentage 
of initial value
The cumulative changes in total vitamin B12, HoloTC, 
MMA and tHcy over time are shown in Fig. 6a. Day 203 
was chosen as the reference point for the initial values 
because it was the first day on which concurrent values 
were obtained for all analytes. Plasma MMA was the most 
sensitive indicator of vitamin B12 deficiency, increasing by 
a maximum of 309  % above the initial value on day 658 
but, as noted above, there were unexplained anomalies. 
Plasma tHcy increased by a maximum of 43 % above the 
initial value on day 609 and, as noted above, was only this 
once above the upper limit of the laboratory reference 
interval value. Total vitamin B12 fell by a maximum of 
53 % below the initial value on day 728, and HoloTC fell 
by a maximum of 66 % below the initial value on day 742.
Analyte concentration as percentage of cut‑off value
The analyte concentrations, as a percentage of the quoted 
cut-off values, of total vitamin B12, HoloTC, MMA and 
tHcy over time are shown in Fig. 6b. Plasma MMA was 
the most sensitive indicator of vitamin B12 deficiency, 
increasing to a maximum of 265  % of the cut-off value 
on day 658 but, as noted above, there were unexplained 
anomalies. Plasma tHcy increased to a maximum of 
104 % of the cut-off value on day 609 and, as noted above, 
was only this once above the upper limit of the labora-
tory reference interval value. Total vitamin B12 fell to a 
minimum of 106 % of the cut-off value on day 728, and 




Haemoglobin and red-cell count were not monitored 
until day 555 because previous self-experimentation had 
shown that this subject’s haematology was unaffected by 
this level of vitamin B12 deficiency. The initial haemo-
globin and red-cell count were 155 g/L and 5.1 × 1012/L 
respectively, both well within the reference normal 
ranges (Fig.  7a). Both fell slightly and insignificantly, to 
149 g/L and 4.9 × 1012/L respectively, by the end of the 
vitamin B12 depletion stage. Both haemoglobin and red-
cell count rose and then fell slightly and insignificantly 
after the cyanocobalamin dose was increased to 1000 μg/
day, with final values of 143 g/L and 4.8 × 1012/L respec-
tively. The overall trend for haemoglobin and red-cell 
count was a slight fall, of 8 and 6 % respectively, not sig-
nificantly affected by the final change in cyanocobalamin 
dose from 0 to 1000 μg/day.
Haematocrit and mean‑cell volume
The initial haematocrit and mean-cell volume were 0.43 
(or 43  %) and 83  fL respectively, on day 555, both well 
within the reference normal ranges (Fig.  7b). There was 
no significant change in either analyte during the remain-
der of the vitamin B12 depletion stage, and neither was 
significantly affected by the final change in cyanocobala-
min dose from 0 to 1000 μg/day.
Analyte concentration correlations and significance: 
vitamin B12 and metabolite assays
Calculations of correlation and significance were per-
formed using Microsoft Excel; complete details may be 
found in table T3 of Additional file 1: Table S1. Charts for 
analyte concentration correlations are shown in Figs. 1b, 
2b, 3b and 4b. Results for Pearson’s correlation coefficient 
(r) and probability (p) are summarised in Table 1.
Total serum vitamin B12 versus holotranscobalamin (HoloTC)
There was a very highly significant positive correlation, 
with r = 0.70), between total serum vitamin B12 and Hol-
oTC concentrations (Fig. 1b; Table 1). This result is con-
sistent with no great difference in sensitivity of the total 
serum vitamin B12, compared to HoloTC, to the onset 
of vitamin B12 deficiency, but does not tell us which the 
most sensitive indicator is. This result is also consist-
ent with the absence of any remarkable differences in 
response over time.
Plasma methylmalonic acid (MMA) 
versus holotranscobalamin (HoloTC)
The negative correlation between MMA and HoloTC 
concentrations was moderate, with r  =  −0.52 (Fig.  2b; 
Table 1). This result is consistent with the observed dif-
ference in sensitivity of the MMA, compared to HoloTC, 
to the onset of vitamin B12 deficiency but does not itself 
tell us which the most sensitive indicator is.
Plasma total homocysteine (tHcy) versus holotranscobalamin 
(HoloTC)
The correlation between tHcy and HoloTC concen-
trations was weak to moderate, with r  =  0.45 (Fig.  3b; 
Table  1). This result is also consistent with the low 
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sensitivity of both the HoloTC and tHcy to the onset of 
vitamin B12 deficiency in this subject.
Total serum vitamin B12 versus plasma methylmalonic acid 
(MMA)
There was a very highly significant negative correlation, 
with r = −0.67, between MMA and total serum vitamin 
B12 concentrations (Fig. 4b; Table 1). This result could be 
consistent with no great difference in sensitivity of the 
MMA, compared to serum vitamin B12, to the onset of 
vitamin B12 deficiency, but is not inconsistent with the 
observed higher sensitivity of the MMA to the onset of 
vitamin B12 deficiency.
Analyte sensitivity comparisons: vitamin B12 
and metabolite assays
Analyte sensitivity comparisons were performed, using 
Microsoft Excel, by comparing the number of concurrent 
pairs of results in each chart quadrant; complete details 
may be found in table T3 of Additional file 1: Table S1. 
Results for counts, for the number of results for each 
analyte pair within each chart quadrant for charts shown 
in Figs. 1b, 2b, 3b and 4b, are summarised in Table 2.
Total serum vitamin B12 versus holotranscobalamin (HoloTC)
The low sensitivity of the HoloTC and total serum vitamin 
B12 concentrations to the onset of vitamin B12 deficiency 
are illustrated in Fig. 1b and Table 2. Of the 95 concurrent 
test results, the 94 data points in the first quadrant show 
serum vitamin B12 above the lower limit of the laboratory 
reference interval of 162  pmol/L (indicating vitamin B12 
adequacy) while HoloTC also is above the lower limit of 
the laboratory reference interval of 35 pmol/L (also indi-
cating vitamin B12 adequacy). The one remaining data 
point is in the second quadrant, showing HoloTC below 
the lower limit of the laboratory reference interval (indi-
cating vitamin B12 deficiency) while total serum vitamin 
B12 is above the lower limit of the laboratory reference 
interval (indicating vitamin B12 adequacy).
Table 1 Results for  correlation coefficient (r) and  p value 
(p)
N = number of concurrent test results for each analyte pair, r = Pearson’s 
correlation coefficient between analyte concentrations, p = p value =  
probability of obtaining the result ≥r, for N concurrent test results, if there is no 
actual linear correlation between analyte concentrations and that the apparent 
correlation is due to random chance
Figure Analytes N r p
1b Total B12 and HoloTC 95 0.70 2.9 × 10−15
2b MMA and HoloTC 52 −0.52 7.6 × 10−5
3b tHcy and HoloTC 52 −0.45 9.2 × 10−4
4b Total B12 and MMA 55 −0.67 2.9 × 10−8
Table 2 Calculated counts for analyte sensitivity compari-
sons
Figure Count criteria Reference Quadrant Count
1b Concurrent B12 and HoloTC 
tests (N)
95
1b B12 ≥162 pmol/L and HoloTC ≥35 pmol/L
L 1 94
1b B12 ≥295 pmol/L and HoloTC ≥35 pmol/L
A 1 41
1b B12 ≥133 pmol/L and HoloTC ≥35 pmol/L
B 1 94
1b B12 ≥162 pmol/L and HoloTC 
<35 pmol/L
L 2 1
1b B12 ≥295 pmol/L and HoloTC 
<35 pmol/L
A 2 0
1b B12 ≥133 pmol/L and HoloTC 
<35 pmol/L
B 2 1
1b B12 <162 pmol/L and HoloTC 
<35 pmol/L
L 3 0
1b B12 <295 pmol/L and HoloTC 
<35 pmol/L
A 3 1
1b B12 <133 pmol/L and HoloTC 
<35 pmol/L
B 3 0
1b B12 <162 pmol/L and HoloTC ≥35 pmol/L
L 4 0
1b B12 <295 pmol/L and HoloTC ≥35 pmol/L
A 4 53
1b B12 <133 pmol/L and HoloTC ≥35 pmol/L
B 4 0
2b Concurrent MMA and HoloTC 
Tests (N)
52
2b MMA ≥0.34 µmol/L and HoloTC 
≥35 pmol/L
L 1 23
2b MMA ≥0.34 µmol/L and HoloTC 
<35 pmol/L
L 2 1
2b MMA <0.34 µmol/L and HoloTC 
<35 pmol/L
L 3 0
2b MMA <0.34 µmol/L and HoloTC 
≥35 pmol/L
L 4 28
3b Concurrent tHcy and HoloTC 
tests (N)
52
3b tHcy ≥13.7 µmol/L and HoloTC 
≥35 pmol/L
L 1 1
3b tHcy ≥13.7 µmol/L and HoloTC 
<35 pmol/L
L 2 0
3b tHcy <13.7 µmol/L and HoloTC 
<35 pmol/L
L 3 1
3b tHcy <13.7 µmol/L and HoloTC 
≥35 pmol/L
L 4 50
4b Concurrent MMA and B12 tests 
(N)
55
4b MMA ≥0.34 µmol/L and B12 ≥162 pmol/L
L 1 24
4b MMA ≥0.34 µmol/L and B12 ≥295 pmol/L
A 1 1
4b MMA ≥0.34 µmol/L and B12 ≥133 pmol/L
B 1 24
4b MMA <0.34 µmol/L and B12 ≥162 pmol/L
L 2 31
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The interpretation of this chart changes significantly 
if reference levels for total serum vitamin B12 concen-
trations from Oh and Brown (2003) are used instead of 
those quoted by the testing laboratory. By increasing the 
minimum total serum vitamin B12 concentration from 
the laboratory reference level of 162–295  pmol/L (Oh 
and Brown 2003), many data points move from the first 
to the fourth quadrant. Using the Bates and Lewis (2012) 
reference level of 133  pmol/L does not move any data 
points from the first to the fourth quadrant.
In the case of the Oh and Brown reference level, of the 
95 concurrent test results, only the 41 data points now 
in the first quadrant show serum vitamin B12 above the 
Oh and Brown reference minimum of 295 pmol/L (indi-
cating vitamin B12 adequacy) while HoloTC also is above 
the lower limit of the laboratory reference interval of 
35 pmol/L (also indicating vitamin B12 adequacy). There 
are now 53 data points in the fourth quadrant, showing 
HoloTC above the lower limit of the laboratory reference 
interval (indicating vitamin B12 adequacy) while total 
serum vitamin B12 is below the Oh and Brown reference 
minimum (indicating vitamin B12 deficiency).
Plasma methylmalonic acid (MMA) 
versus holotranscobalamin (HoloTC)
The low sensitivity of the HoloTC concentration to the 
onset of vitamin B12 deficiency, compared to MMA, is 
illustrated in Fig.  2b and Table  2. Of the 52 concurrent 
test results, the 23 data points in the first quadrant show 
MMA above the upper limit of the laboratory reference 
interval of 0.34  µmol/L (indicating vitamin B12 defi-
ciency) while HoloTC is above the lower limit of the labo-
ratory reference interval of 35 pmol/L (indicating vitamin 
B12 adequacy). Only one data point is in the second quad-
rant, showing MMA above the upper limit of the labora-
tory reference interval while HoloTC is below the lower 
limit of the laboratory reference interval (both indicating 
vitamin B12 deficiency). The remaining 28 data points are 
in the fourth quadrant, showing MMA below the upper 
limit of the laboratory reference interval while HoloTC is 
above the lower limit of the laboratory reference interval 
(both indicating vitamin B12 adequacy).
Plasma total homocysteine (tHcy) versus holotranscobalamin 
(HoloTC)
The low sensitivity of the HoloTC and tHcy concentra-
tions to the onset of vitamin B12 deficiency are illustrated 
in Fig. 3b and Table 2. Of the 52 concurrent test results, 
the one data point in the first quadrant shows tHcy above 
the upper limit of the laboratory reference interval of 
13.7  μmol/L (indicating vitamin B12 deficiency) while 
HoloTC is above the lower limit of the laboratory refer-
ence interval of 35  pmol/L (indicating vitamin B12 ade-
quacy). One data point is in the third quadrant, showing 
tHcy below the upper limit of the laboratory reference 
interval (indicating vitamin B12 adequacy) while HoloTC 
is above the lower limit of the laboratory reference inter-
val (indicating vitamin B12 deficiency). The remaining 
50 data points are in the fourth quadrant, showing tHcy 
below the upper limit of the laboratory reference interval 
while HoloTC is above the lower limit of the laboratory 
reference interval (both indicating vitamin B12 adequacy).
Total serum vitamin B12 versus plasma methylmalonic acid 
(MMA)
The high sensitivity of the MMA and low sensitivity 
of total serum vitamin B12 concentrations to the onset 
of vitamin B12 deficiency are illustrated in Fig.  4b and 
Table  2. Of the 55 concurrent test results, the 24 data 
points in the first quadrant show MMA above the upper 
limit of the laboratory reference interval 0.34  µmol/L 
(indicating vitamin B12 deficiency) while total serum 
vitamin B12 is above the lower limit of the laboratory 
Table 2 continued
Figure Count criteria Reference Quadrant Count
4b MMA <0.34 µmol/L and B12 ≥295 pmol/L
A 2 20
4b MMA <0.34 µmol/L and B12 ≥133 pmol/L
B 2 31
4b MMA <0.34 µmol/L and B12 
<162 pmol/L
L 3 0
4b MMA <0.34 µmol/L and B12 
<295 pmol/L
A 3 11
4b MMA <0.34 µmol/L and B12 
<133 pmol/L
B 3 0
4b MMA ≥0.34 µmol/L and B12 
<162 pmol/L
L 4 0
4b MMA ≥0.34 µmol/L and B12 
<295 pmol/L
A 4 23
4b MMA ≥0.34 µmol/L and B12 
<133 pmol/L
B 4 0
Reference L = analyte concentration limit defined by the testing laboratory, 
reference A = analyte concentration limit defined by Oh and Brown (2003), 
reference B = analyte concentration limit defined by Bates and Lewis (2012), 
Quadrant = chart quadrant: 
Quadrant 2 Quadrant 1 
Quadrant 3 Quadrant 4 
, 
Count = number of concurrent analyte pair concentration results within each 
quadrant
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reference interval of 162 pmol/L (indicating vitamin B12 
adequacy). The remaining 31 data points are in the sec-
ond quadrant, showing MMA below the upper limit of 
the laboratory reference interval (indicating vitamin B12 
adequacy) while total serum vitamin B12 also is above the 
lower limit of the laboratory reference interval (also indi-
cating vitamin B12 adequacy).
As with the previous chart, the interpretation changes 
significantly if reference levels for total serum vita-
min B12 concentrations from Oh and Brown (2003) 
are used instead of those quoted by the testing labora-
tory. By increasing the minimum total serum vitamin 
B12 concentration from the laboratory reference level 
of 162–295  pmol/L (Oh and Brown 2003), many data 
points move from the first and second quadrants to the 
fourth and third quadrants respectively. Using the Bates 
and Lewis (2012) reference level of 180 pmol/L does not 
move any data points between quadrants.
In the case of the Oh and Brown reference level, the 
single data point remaining in the first quadrant shows 
MMA above the upper limit of the laboratory reference 
interval 0.34 µmol/L (indicating vitamin B12 deficiency) 
while total serum vitamin B12 is above the lower limit 
of the laboratory reference interval of (indicating vita-
min B12 adequacy). There are now 20 data points in the 
second quadrant, showing MMA below the upper limit 
of the laboratory reference interval (indicating vitamin 
B12 adequacy) while total serum vitamin B12 is above 
the Oh and Brown reference minimum (also indicating 
vitamin B12 adequacy). There are now 11 data points 
in the third quadrant, showing MMA below the upper 
limit of the laboratory reference interval (indicating 
vitamin B12 adequacy) while total serum vitamin B12 
also is below the Oh and Brown reference minimum 
(indicating vitamin B12 deficiency). The remaining 
23 data points are now in the fourth quadrant, show-
ing MMA above the upper limit of the laboratory ref-
erence interval (indicating vitamin B12 deficiency) 
while total serum vitamin B12 also is below the Oh and 
Brown reference minimum (also indicating vitamin B12 
deficiency).
The subject
The subject’s weight did not change significantly dur-
ing the course of the experiment. He observed worsen-
ing neurological symptoms including extreme mental 
tiredness, and unpleasant micro-dreams in the daytime. 
The subject also observed significant reduction in tac-
tile sense in his extremities (peripheral neuropathy), and 
severe physical fatigue. Recovery following resumption of 
oral vitamin B12 treatment was very slow.
Discussion
Experimental findings
Serum total vitamin B12 versus serum holotranscobalamin 
(HoloTC)
Three graphical methods have shown that serum HoloTC 
was only slightly more sensitive to the onset of vitamin 
B12 deficiency than serum total vitamin B12, with HoloTC 
indicating vitamin B12 deficiency and serum total vitamin 
B12 indicating vitamin B12 adequacy for only 1 of the 95 
concurrent tests. Firstly, there were no remarkable dif-
ferences in the time charts for the two analyte concen-
trations (Figs.  1a, 6). Secondly, there was a very highly 
significant positive correlation between serum total vita-
min B12 and HoloTC concentrations (Fig.  1b; Table  1), 
consistent with the similar responses over time. Thirdly, 
all except one data point were in the first quadrant of 
the analyte sensitivity comparison chart, indicating that 
both analytes were within the normal range for 94 of the 
95 concurrent tests when using the laboratory reference 
level serum total vitamin B12 (Fig. 1b; Table 2).
It is important to note that the relative sensitivities 
can be very significantly altered by changing the ref-
erence level for either or both analytes. By using the 
Oh and Brown (2003) reference level (295  pmol/L) for 
serum total vitamin B12, instead of the lower limit of the 
laboratory reference interval for serum total vitamin B12 
(162  pmol/L), HoloTC becomes far less sensitive than 
serum total vitamin B12 to the onset of vitamin B12 defi-
ciency (Fig. 1a, b).
Plasma methylmalonic acid (MMA) versus serum 
holotranscobalamin (HoloTC)
Three graphical methods have shown that serum Hol-
oTC was far less sensitive to the onset of vitamin B12 defi-
ciency than plasma MMA, with serum HoloTC indicating 
vitamin B12 adequacy while MMA indicated vitamin B12 
deficiency for 23 of the 52 concurrent tests. Firstly, there 
were very remarkable differences in the time charts for 
the two analyte concentrations (Figs.  2a, 6). Secondly, 
although there was a moderate correlation between 
MMA and HoloTC concentrations (Fig. 2b; Table 1), this 
is not inconsistent with the different responses over time. 
Thirdly, only one data point was in the second quadrant 
of the analyte sensitivity comparison chart, indicating 
that HoloTC was below the lower limit of the laboratory 
reference interval of 35  pmol/L only once, whereas 23 
of the 52 data points were in the first quadrant, indicat-
ing that MMA was above the upper limit of the labora-
tory reference interval of 0.34 µmol/L while HoloTC was 
above the lower limit of the laboratory reference interval 
(Fig. 2b; Table 2).
Page 15 of 17Golding  SpringerPlus  (2016) 5:184 
Although plasma MMA showed the greatest sensitivity 
to the onset of vitamin B12 deficiency, the results included 
several unexplained anomalies (Figs. 2a, 6).
Plasma total homocysteine (tHcy) versus serum 
holotranscobalamin (HoloTC)
Three graphical methods have shown that serum HoloTC 
was similarly insensitive to the onset of vitamin B12 defi-
ciency as plasma tHcy, with both indicating vitamin B12 
adequacy for 50 of the 52 concurrent tests. Firstly, there 
were no remarkable differences in the time charts for 
the two analyte concentrations except that, as expected, 
they tended to change in opposite directions (Figs.  3a, 
6). Secondly, there was a weak to moderate correla-
tion between tHcy and HoloTC concentrations (Fig. 3b; 
Table 1), not inconsistent with both having low sensitivity 
to the onset of vitamin B12 deficiency. Thirdly, 50 of the 
52 data points were in the fourth quadrant of the analyte 
sensitivity comparison chart, indicating that HoloTC was 
above the lower limit of the laboratory reference interval 
of 35  pmol/L while tHcy was below the upper limit of 
the laboratory reference interval of 13.7 μmol/L (Fig. 3b; 
Table 2).
The low sensitivity of the homocysteine is consistent 
with the absence of any significant haematological affects 
(Fig. 7a, b). The absence of anaemia does not rule out vita-
min B12 deficiency; as noted by Lindenbaum et al. (1988), 
28 % of patients with neurological affects due to vitamin 
B12 deficiency have no haematological abnormalities.
Comparison with previous experimental findings
The results of this experiment are inconsistent with the 
reported findings that HoloTC was the most sensitive 
and earliest marker of vitamin B12 deficiency. Firstly, Hol-
oTC was not significantly more sensitive than total vita-
min B12 to the depletion of the vitamin B12 body store 
(Figs. 1, 6). Secondly, MMA overtly showed a disturbed 
metabolism well before HoloTC indicated any vitamin 
B12 deficiency (Figs. 2, 6).
As noted earlier in this discussion, it is possible to alter 
the apparent relative sensitivity of any pair of analytes 
by selectively changing the cut-off value of one or both 
of them. As demonstrated in this experiment, select-
ing different cut-off values for total vitamin B12 changed 
the relative sensitivities of HoloTC and total vitamin 
B12 (Fig. 1a, b); the same applies to the cut-off value for 
HoloTC. When the HoloTC cut-off is increased, the sen-
sitivity to vitamin B12 deficiency is increased, but the 
specificity of the test is reduced, increasing the number 
of false positive results. Conversely, if the HoloTC cut-off 
is decreased, the specificity of the test is increased, but 
the sensitivity of the test is reduced, increasing the num-
ber of false negative results.
The results of this experiment are consistent with the 
findings of several researchers whose results do not sup-
port the claim that HoloTC is a significantly earlier and 
more sensitive indicator of vitamin B12 deficiency than 
total vitamin B12 and its metabolites (Miller et  al. 2005; 
Clarke et  al. 2007; Schrempf et  al. 2011; Palacios et  al. 
2013; Remacha et  al. 2014). These studies all involved 
aged patients whose vitamin B12 deficiency was likely 
to have been caused by food-cobalamin malabsorption 
(Carmel 1995; Andrès et  al. 2004). Miller et  al. (2005) 
concluded that “HoloTC and total vitamin B12 have equal 
diagnostic accuracy in screening for metabolic vitamin 
B12 deficiency”. Clarke et  al. (2007) reported “modest” 
superiority of the HoloTC immunoassay, but concluded 
that neither HoloTC nor total vitamin B12 was suitable 
for screening for vitamin B12 deficiency. Schrempf et al. 
(2011) reported that “holoTC does not show superior 
diagnostic accuracy compared to VitB12 for the detection 
of VitB12 deficiency in subjects with neuropsychiatric 
conditions”. Palacios et al. (2013) found that HoloTC sen-
sitivity was only 44 %, and concluded that it was unsuit-
able for screening alone. Remacha et al. (2014) concluded 
that “These data do not support HoloTC as the earliest 
marker of Cbl deficiency and challenge the classification 
in stages of Cbl deficiency”.
Herbert’s model
The results of this experiment are inconsistent with Her-
bert’s model for sequential stages in the development of 
vitamin B12 deficiency, in which HoloTC is the earli-
est marker of the change from Normal to Early Nega-
tive B12 Balance (Herbert 1987a, 1994). Firstly, because 
the responses of HoloTC and total vitamin B12 were so 
similar, these results do not support the hypothesis that 
HoloTC is an earlier or more sensitive indicator of a tran-
sition between normal and negative balance conditions 
(Figs. 1, 6). Secondly, as stated above, MMA overtly indi-
cated a disturbed metabolism well before HoloTC indi-
cated any vitamin B12 deficiency (Figs. 2, 6).
Limitations of the experiment
Number of subjects
Because this subject has vitamin B12 deficiency suspected 
of being caused by a defect in intracellular metabolism, a 
relatively rare condition, he might not represent a typical 
patient. The sensitivity of HoloTC to the onset of a defi-
ciency condition, compared to total vitamin B12 and the 
metabolites, is likely to depend on the specific cause of 
the deficiency.
For ethical reasons, a longitudinal experiment designed 
to produce vitamin B12 deficiency can only be performed 
by means of self-experimentation on a single subject. It 
is therefore not possible to investigate the longitudinal 
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performance of the HoloTC immunoassay for a large 
group of subjects.
Even if there were no ethical objections to the per-
formance of such an experiment, it would be of limited 
value. This is because a pure dietary vitamin B12 defi-
ciency, induced for the purpose of the experiment, would 
not necessarily produce the same effect on HoloTC as 
would other causes of deficiency such as malabsorption. 
In dietary deficiency, enterohepatic recycling tends to 
maintain the HoloTC concentration until the liver store 
of vitamin B12 is exhausted; when deficiency develops 
due to the onset of severe malabsorption, the recycling 
would become ineffective and produce a faster reduction 
in HoloTC concentration because it has a very short half-
life in serum. (Herbert 1994).
According to Allen B. Weisse (2012), “many self-exper-
iments have proved invaluable to the medical commu-
nity and to the patients we are seeking to help.” There are 
numerous other examples of significant contributions 
made to medical science by single subject experiments 
(Altman 1998; Widdowson 1993).
Number of laboratories
To eliminate individual laboratory error, it would be 
desirable to have samples tested by more than one labo-
ratory for each analyte. This was not practical because of 
the high cost, and logistical problems including the need 
to draw excessive volumes of blood from the subject on 
each sampling day. For the vitamin B12 and HoloTC tests, 
with modern automated immunoassay systems using 
pre-packaged reagent kits, the likelihood of significant 
individual laboratory error has been reduced. For the 
metabolites, MMA and homocysteine, the specialised 
laboratory had very strict quality-control procedures. 
Taking these factors into account, and the very large 
number of sampling days over such a long time span, it 
is unlikely that the results can be explained by individual 
laboratory error.
Conclusions
The results of this experiment are inconsistent with Her-
bert’s hypothesis that HoloTC is the earliest marker of 
vitamin B12 deficiency, and therefore do not support his 
model for the staged development of vitamin B12 defi-
ciency. MMA was the most sensitive indicator of vitamin 
B12 deficiency but results contained significant unex-
plained anomalies. Self-experimentation has produced 
a detailed record of the response of HoloTC to experi-
mental vitamin B12 deficiency, whereas using patients or 
healthy volunteers as subjects would be unethical.
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